About this Research Topic
PANoptosis, an emerging concept in immunology, refers to a form of programmed cell death that integrates various signaling pathways, including pyroptosis, apoptosis, and necroptosis. This multifaceted process plays a crucial role in regulating immune responses and maintaining cellular homeostasis.
T-cell-based immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells. Approaches such as chimeric antigen receptor (CAR) T cell therapy and immune checkpoint blockade have shown remarkable success in certain cancers. However, challenges remain, including resistance to therapy and adverse effects on normal tissues. In recent years, there has been increasing interest in understanding the role of PANoptosis in T cell-based immunotherapy, particularly in the context of cancer treatment.
PANoptosis has emerged as a potential mechanism underlying the efficacy and limitations of T cell-based immunotherapy. By modulating the activation and death of immune cells, including T cells, PANoptosis influences the outcome of immunotherapy interventions. Additionally, dysregulation of PANoptosis pathways may contribute to immune evasion by cancer cells and resistance to immunotherapy. Understanding the intricate interplay between PANoptosis and T cell responses is essential for optimizing the efficacy and safety of T cell-based immunotherapy. Insights into the molecular mechanisms governing PANoptosis may lead to the development of novel therapeutic strategies aimed at enhancing anti-tumor immune responses and overcoming treatment resistance.
This Research Topic welcomes submissions that investigate various aspects of PANoptosis, including its molecular mechanisms, regulation, and impact on T cell function and immunotherapy outcomes. Topics of interest include, but are not limited to:
- Molecular pathways and signaling cascades involved in PANoptosis.
- Crosstalk between PANoptosis and other cell death pathways in T cells.
- The role of PANoptosis in modulating T cell activation, proliferation, and differentiation.
- Regulation of PANoptosis by immune checkpoint molecules and therapeutic interventions.
- Preclinical and clinical studies evaluating the therapeutic potential of targeting PANoptosis in T cell-based immunotherapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
T-cell-based immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells. Approaches such as chimeric antigen receptor (CAR) T cell therapy and immune checkpoint blockade have shown remarkable success in certain cancers. However, challenges remain, including resistance to therapy and adverse effects on normal tissues. In recent years, there has been increasing interest in understanding the role of PANoptosis in T cell-based immunotherapy, particularly in the context of cancer treatment.
PANoptosis has emerged as a potential mechanism underlying the efficacy and limitations of T cell-based immunotherapy. By modulating the activation and death of immune cells, including T cells, PANoptosis influences the outcome of immunotherapy interventions. Additionally, dysregulation of PANoptosis pathways may contribute to immune evasion by cancer cells and resistance to immunotherapy. Understanding the intricate interplay between PANoptosis and T cell responses is essential for optimizing the efficacy and safety of T cell-based immunotherapy. Insights into the molecular mechanisms governing PANoptosis may lead to the development of novel therapeutic strategies aimed at enhancing anti-tumor immune responses and overcoming treatment resistance.
This Research Topic welcomes submissions that investigate various aspects of PANoptosis, including its molecular mechanisms, regulation, and impact on T cell function and immunotherapy outcomes. Topics of interest include, but are not limited to:
- Molecular pathways and signaling cascades involved in PANoptosis.
- Crosstalk between PANoptosis and other cell death pathways in T cells.
- The role of PANoptosis in modulating T cell activation, proliferation, and differentiation.
- Regulation of PANoptosis by immune checkpoint molecules and therapeutic interventions.
- Preclinical and clinical studies evaluating the therapeutic potential of targeting PANoptosis in T cell-based immunotherapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: PANoptosis, T cell-based immunotherapy, immunotherapy, CAR-T
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
